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Abstract: AIM OF THE STUDY In Switzerland, clinical practice guidelines (CPGs) are not generally
registered by a single central institution. Therefore, the total number and overall quality of the existing
guidelines are not known. Our aim was to identify and describe the characteristics of current CPGs
developed or endorsed by Swiss medical societies, by conducting a comprehensive systematic search.
METHODS A systematic search was done in two medical literature databases (PubMed and OVID),
two major non-indexed Swiss medical journals, Swiss medical societies’ websites and the FMH guidelines
platform. Synonyms of “guidelines” in English, German, French and Italian were used as search terms,
complemented by a hand search. Inclusion criteria for the retrieved documents were that they: (1)
contained recommendations for patient care provided by physicians; (2) defined specific clinical circum-
stances; (3) were developed, adapted or endorsed by one of the Swiss national medical specialty societies.
Documents with publication date before 1 January 2008 or containing only general and public health
recommendations were excluded. Retrieved documents were screened by two reviewers in parallel. Data
on the reported methods as well as transparency and quality indicators of the CPGs were extracted in
a standardised way. RESULTS A total of 295 CPGs were included in the analysis, 199 of which were
found only on the societies’ websites, 44 only in the literature and 13 only on the FMH platform. Overall,
159 (54%) of guidelines had at least one predefined keyword in the title, most frequently “Empfehlung”
or “guideline”. Health areas with the highest number of CPGs were cardiovascular (55) and infectious
(52) diseases. Most CPGs were developed in Switzerland (212); the rest were developed in cooperation
with German societies (6) or with both German and Austrian societies (23), or by other international
organisations (54). At least one author and the date of publication were reported in 83% and 94% of
guidelines, respectively. Conflicts of interest were stated in 44% and financial support documented in
29% of the guidelines. Any method of guideline development was mentioned in 56%. CONCLUSIONS
Numerous CPGs provide recommendations for clinical practice in Switzerland. The majority are pub-
lished on medical societies’ websites only. The quality of reporting is extremely heterogeneous, ranging
from documents without reported authors, methods of development and publication date, to graded,
continuously updated guidelines based on a systematic review of evidence. CPGs could potentially be
improved by using a standardised development and reporting framework.
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Summary
AIM OF THE STUDY: In Switzerland, clinical practice
guidelines (CPGs) are not generally registered by a single
central institution. Therefore, the total number and overall
quality of the existing guidelines are not known. Our aim
was to identify and describe the characteristics of current
CPGs developed or endorsed by Swiss medical societies,
by conducting a comprehensive systematic search.
METHODS: A systematic search was done in two medical
literature databases (PubMed and OVID), two major non-
indexed Swiss medical journals, Swiss medical societies’
websites and the FMH guidelines platform. Synonyms of
“guidelines” in English, German, French and Italian were
used as search terms, complemented by a hand search.
Inclusion criteria for the retrieved documents were that
they: (1) contained recommendations for patient care pro-
vided by physicians; (2) defined specific clinical circum-
stances; (3) were developed, adapted or endorsed by one
of the Swiss national medical specialty societies. Docu-
ments with publication date before 1 January 2008 or con-
taining only general and public health recommendations
were excluded. Retrieved documents were screened by
two reviewers in parallel. Data on the reported methods
as well as transparency and quality indicators of the CPGs
were extracted in a standardised way.
RESULTS: A total of 295 CPGs were included in the
analysis, 199 of which were found only on the societies’
websites, 44 only in the literature and 13 only on the
FMH platform. Overall, 159 (54%) of guidelines had at
least one predefined keyword in the title, most frequently
“Empfehlung” or “guideline”. Health areas with the highest
number of CPGs were cardiovascular (55) and infectious
(52) diseases. Most CPGs were developed in Switzerland
(212); the rest were developed in cooperation with Ger-
man societies (6) or with both German and Austrian soci-
eties (23), or by other international organisations (54). At
least one author and the date of publication were report-
ed in 83% and 94% of guidelines, respectively. Conflicts
of interest were stated in 44% and financial support docu-
mented in 29% of the guidelines. Any method of guideline
development was mentioned in 56%.
CONCLUSIONS: Numerous CPGs provide recommenda-
tions for clinical practice in Switzerland. The majority are
published on medical societies’ websites only. The quality
of reporting is extremely heterogeneous, ranging from
documents without reported authors, methods of develop-
ment and publication date, to graded, continuously updat-
ed guidelines based on a systematic review of evidence.
CPGs could potentially be improved by using a standard-
ised development and reporting framework.
Keywords: clinical practice guideline, guideline, Switzer-
land, medical societies
Introduction
Clinical practice guidelines (CPGs) provide systematically
developed recommendations for medical doctors with the
aim of optimising patient care [1, 2]. Their development
in Switzerland is promoted by the Swiss Medical Associa-
tion (FMH), as well as by the Swiss Academy of Arts and
Sciences [3, 4]. Both organisations recognise medical so-
cieties as key players in CPG adaptation, adoption and de-
velopment.
In contrast to some neighbouring countries, Switzerland
has no single central institution to coordinate national CPG
development [5]. Therefore, there is currently no compre-
hensive source of all national guidelines. Apart from a
survey in 2001 [6], the overall CPG development efforts
of Swiss medical societies have rarely been studied. With
the aim to improve transparency and to interconnect CPG
developers, FMH launched a platform for documenting
Swiss CPGs in 2017 [7]. The submission of CPGs to the
platform is voluntary, and it is unknown what fraction of
all relevant CPGs is collected. A systematic effort to re-
view all national guidelines has been undertaken in a few
other countries [8], often limiting the scope to high quality
[9] or single specialty [10] CPGs. No such systematic re-
view of similar extent exists for Switzerland.
The aim of this study was to collect and review all current
clinical practice guidelines developed or endorsed in
Switzerland by medical societies. To achieve this, we sys-
tematically searched the scientific literature, Swiss medical
societies’ websites and the FMH platform for guidelines.
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definition of clinical practice guidelines and extracted in-
dicators of their development, transparency and reporting
methods.
Methods
The study was completed in two stages. In the first part
of the study, we completed a systematic search for Swiss
CPGs. Secondly, we extracted development and reporting
data from the retrieved CPGs, and analysed the results. The
study used principles of a systematic review and adhered
to the reporting standards proposed in the PRISMA state-
ment [11].
Search strategy
A broad search was performed to obtain a comprehensive
overview of all CPGs developed or endorsed by Swiss
medical societies. It included four sources: two literature
search engines (PubMed and OVID), the archives of two
major non-indexed Swiss medical journals (Schweiz-
erische Ärztezeitung and Swiss Medical Forum), medical
societies’ websites and the FMH guidelines platform at
guidelines.fmh.ch. A list of synonyms of the word “guide-
line” in English, German, French and Italian was created.
This CPG keyword list was used in the literature and jour-
nal archives search. Both searches were performed in June
2018. In PubMed and OVID, results were limited to publi-
cation date from 2008. From the journal archives, all arti-
cles containing a CPG keyword in the title were retrieved.
A primary list of medical societies was compiled from the
societies listed on the FMH website [12]. On the websites
of these societies, a hand search was performed to identi-
fy additional sub- or inter-speciality societies. All collect-
ed websites were then searched for potential CPGs by a
protocol-assisted hand search in September 2018. If a po-
tential CPG was available in multiple languages, only one
version was retrieved. Priority was given to English docu-
ments, followed by German, French and Italian. All guide-
lines submitted to the FMH platform were retrieved in No-
vember 2018. Documents that were not openly accessible
were ignored. Items for which no full text document was
found via the respective literature database are reported in
figure 1. The search query for PubMed, strategy for the
websites and the list of websites searched are given in ap-
pendix 1.
Screening
The selection criteria were formulated by all three authors
(LB, AU, HD) and are analogous to the ones used in an
Australian study [8]. A guideline was considered as en-
dorsed if listed on the website of a society or submitted to
the FMH platform by a medical society.
For inclusion, documents had to: (1) include recommenda-
tions intended to optimise patient care provided by medical
doctors, (2) address specific clinical circumstances and (3)
be produced, adapted or endorsed by a public Swiss nation-
al medical speciality society (“Fachgesellschaft”). Docu-
ments were excluded if they (1) had a publication date
before 1 January 2008, or were (2) publications on den-
tal medicine, (3) dietary recommendations for the general
public or not meant primarily for advice given to patients
by medical doctors, (4) public health recommendations
aimed to optimise non-individualised prevention measures,
the healthcare system or population health or (5) general
advice on physician services and conduct, without speci-
fied clinical circumstances or patient population.
The screening was conducted by two authors (AU, LB)
separately, disagreements were settled bilaterally or, if nec-
essary, by a decision of the third author (HD). Search re-
sults from literature databases and journal archives were
first screened by title and abstract, then a full text screening
for all sources was performed.
The search and screening process is depicted in figure 1.
Data extraction and analysis
The extracted variables were based on adapted “Key Com-
ponents of High-Quality and Trustworthy Guidelines”,
proposed by the Guidelines International Network [13],
and were predefined before data extraction. The variables
correspond broadly to guideline development (e.g., pub-
lication and expiry dates), transparency (e.g., declaration
of conflicts of interest and financial support) and methods
(e.g., reporting of references and rating of evidence or
recommendations). We also extracted guideline-signalling
keywords from the title, and the health area reflected by
the guideline (based on categories used in a similar review
[8]).
The following categorical variables were extracted: health
area reflected by the guideline, keyword in title, coun-
try(ies) of origin of the authoring societies and financial
support for guideline development. Furthermore, the fol-
lowing binary (yes/no) variables were extracted: reporting
of the publication and expiry dates, authors, their conflicts
of interest, any methods of guideline development, deci-
sion making process, references, review of evidence, and
rating of evidence and recommendations. Data were en-
tered in a custom-made Excel document as a selection
from predefined options for each variable. Data extraction
was tested by reviewers in duplicate on a set of ten and
subsequently 30 guidelines, to clarify the definitions of
variables.
Data were extracted by two reviewers in duplicate (AU and
LB) for sets of 30 guidelines sequentially. Inter-rater agree-
ment of data entries was calculated, and the discordant data
entries were resolved by discussion among the authors.
The process was repeated until a pre-specified inter-rater
agreement above 95% before the discussion was reached.
After the second set of 30 guidelines, 95.5% agreement
was reached, and the remaining guidelines were randomly
assigned for data extraction to a single reviewer (AU or
LB).
A single source of the finally selected set of guidelines (lit-
erature search, societies’ websites or FMH guideline data-
base) was recorded in the review.
Extracted data were analysed using Microsoft Excel and R
[14].
Results
The PRISMA flowchart of the guideline selection is shown
in figure 1. We identified 1105, 458 and 149 documents
in the literature, websites and FMH platform, respectively.
After removal of duplicates and screening for the inclusion
and exclusion criteria, 295 documents were included in the
final analysis. From these, 199 were found only on the so-
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cieties’ websites, 44 only in the literature and 13 only in
the FMH platform. Thirty-nine guidelines were found on
at least two of these sources. The distribution of guidelines
by their source is shown in figure 2. A list of the included
guidelines is provided in appendix 2.
In total, 159 (54%) of the included CPGs had at least
one predefined keyword in the title. “Empfehlung” and
“guideline” were the most frequent keywords, mentioned
63 (21%) and 46 (16%) times, respectively. Health areas
with the most numerous corresponding CPGs were cardio-
vascular and infectious diseases, 55 (19%) and 52 (18%) of
CPGs, respectively (table 1). Seventy-six CPGs were ini-
tially assigned to the category “other”, and upon review-
ing included rheumatology (22), neurology (8), anaesthesi-
ology and reanimatology (8), gynaecology (7), allergology
(6), dermatology (5), palliative care (5), and other special-
ties (15) CPGs. Overall, 212 (72%) of included CPGs were
developed by Swiss medical societies or authors affiliat-
ed with Swiss medical institutions, 6 (2%) with coopera-
tion of German physician societies only, 23 (8%) with co-
operation of German and Austrian physician societies, and
54 (18%) were developed by European, American or oth-
er physician societies, with or without explicit contribution
from Switzerland.
Guidelines reflecting different health areas had differing
distributions by country of origin (table 1). Cardiovascular
diseases guidelines were developed by international so-
cieties or in cooperation with other countries frequently
(69% of cardiovascular guidelines), whereas pregnancy
and childbirth guidelines were developed in cooperation
with Austrian and German physician societies frequently
(29% of the guidelines).
Figure 1: PRISMA flowchart of guideline search, screening and inclusion.
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Reporting of guideline development was incomplete in
many of the guidelines (table 2). At least one guideline au-
thor (member of the guideline developing team) was re-
ported in 246 (83%), and the publication date in 276 (94%)
of the CPGs. However, an expiry date was provided in only
48 (16%). A conflict of interest statement was provided di-
rectly or via a reference in 139 (44%), and a declaration
of financial support for the guideline development in 86
(29%) of the included guidelines. Of these 86 guidelines,
Figure 2: Sources of the guidelines included in the review.Litera-
ture – scientific literature databases and archives of two major
non-indexed Swiss medical journals, Platform – FMH guidelines
platform guidelines.fmh.ch, Websites – Swiss medical societies’
websites.
19 (22%) reported no financial support, 10 (12%) support
from industry and 57 (66%) support from non-industry re-
lated sources.
Any method of guideline development was reported in 165
(56%) guidelines (table 2). A total of 239 (81%) guide-
lines provided at least some references to the evidence and
evidence syntheses used for the guideline development,
but only 29 (10%) claimed in the methods to have used a
systematic review of evidence. Thirty-six (12%) of CPGs
described some procedure of decision making to reach a
consensus in the guideline recommendation statements (13
Nominal group, 5 Delphi, 18 modified, combined or oth-
er methods). A system of evidence quality rating was de-
fined and used in 68 (23%), and a system of recommenda-
tion strength rating in 60 (20%) CPGs.
Keywords in the title were associated with different fre-
quencies of using the methodology of a systematic review
(fig. 3). A systematic review was performed in CPGs titled
“Leitlinie” most frequently (58% of “Leitlinie”). Country
of origin was also associated with the type of evidence re-
view (fig. 4). Guidelines developed in Switzerland (with-
out international cooperation) reported a systematic review
of evidence least frequently (2%), and it was more preva-
lent with an international cooperation between Switzer-
land, Germany and Austria or other countries (fig. 4).
Table 1: Health area and country(ies) of origin.
Health area Developed in Total






Cancer 10 (56%) 0 (0%) 2 (11%) 6 (33%) 18
Cardiovascular disease 16 (29%) 0 (0%) 1 (2%) 38 (69%) 55
Diabetes 19 (100%) 0 (0%) 0 (0%) 0 (0%) 19
Drugs and alcohol 2 (50%) 0 (0%) 1 (25%) 1 (25%) 4
Infectious diseases 49 (94%) 0 (0%) 2 (4%) 1 (2%) 52
Injury 3 (75%) 0 (0%) 0 (0%) 1 (25%) 4
Mental health 19 (100%) 0 (0%) 0 (0%) 0 (0%) 19
Musculoskeletal disease 6 (86%) 0 (0%) 1 (14%) 0 (0%) 7
Non-infectious pulmonary
disease
12 (80%) 1 (7%) 1 (7%) 1 (7%) 15
Obesity 3 (100%) 0 (0%) 0 (0%) 0 (0%) 3
Pregnancy and childbirth 13 (62%) 0 (0%) 6 (29%) 2 (10%) 21
Renal disease 2 (100%) 0 (0%) 0 (0%) 0 (0%) 2
Other 58 (76%) 5 (7%) 9 (12%) 4 (5%) 76
Total 212 (72%) 6 (2%) 23 (8%) 54 (18%) 295
Table 2: Quality and transparency indicators.
Total number of CPGs = 295
Yes No
One or more members of guideline development group listed 246 (83%) 49 (17%)
Conflict of interest statement 129 (44%) 166 (56%)
Publication date 276 (94%) 19 (6%)
Expiration date 48 (16%) 247 (84%)
Declaration of funding/other support 86 (29%) 209 (71%)
References 239 (81%) 56 (19%)
Systematic review of evidence 29 (10%) 266 (90%)
Decision-making process described 36 (12%) 259 (88%)
Any method described 165 (56%) 130 (44%)
Rating of evidence 68 (23%) 227 (77%)
Rating of recommendation 60 (20%) 235 (80%)
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Figure 3: Keyword in title of guideline and review of evidenceOnly keywords with more than two corresponding guidelines included are shown
(“guida” and “racommandation” had a single guideline each). Three CPGs had two keywords in the title and were assigned for both categories
in the table.
Discussion
We identified 295 clinical practice guidelines (CPGs) de-
veloped or endorsed by Swiss medical societies and pub-
lished after 2008. The majority of CPGs reported basic ele-
ments of development (at least one author, publication date
and at least some references). However, many other key
components of high-quality CPGs [13], such as reporting
of conflict of interests of authors and financial support for
the guideline, a systematic review of evidence, the deci-
sion-making process, and rating of evidence or recommen-
dations, were present only in a minority of the analysed
CPGs.
Figure 4: Country of origin and review of evidence.
Because of different study methodologies, the total number
of CPGs found is difficult to compare with those in other
studies. In 2001, a survey of 46 Swiss medical societies
reported 84 guidelines produced or endorsed in Switzer-
land [6]. In Australia, 313 CPGs were identified [8], in-
cluding regional CPGs and guidelines produced by govern-
ment agencies. A study in Argentina identified 144 CPGs
when guidelines with no development method described
were excluded [9]. The number of CPGs identified de-
pends also on the time span analysed (2008–2018 in our
study, 1974–1999 in [6], 2003–2007 in [8] and 1994–2004
in [9]).
For inclusion in our study, documents did not have to fully
meet the often cited American Institute of Medicine def-
inition of a CPG [1], which implies a systematic review
of evidence and an assessment of benefit and harms of
alternative care options. Applying such a strict definition
might only give a limited view on guidelines in the broader
sense – documents intended to optimise patient care pro-
vided by physicians. However, we did restrict the analysis
to CPGs developed or endorsed by national medical so-
cieties, excluding guidelines authored by physician net-
works, cantonal bodies or hospitals. Similarly, “Choosing
Wisely” lists were not the focus of our study. Still, six of
these lists of recommendations are included in this review.
Admittedly, such guidelines could have a significant local
impact on medical practice. The analysis of these CPGs, as
well as the uptake and applicability of the different types of
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guidelines in Switzerland, will have to be explored in fu-
ture studies.
Most CPGs were found on websites only (see fig. 2), po-
tentially rendering them difficult to find for researchers,
practitioners and policy makers. During the search process
in this study, we observed that CPGs on societies’ websites
are not always easily found (e.g., archived in various and
sometimes non-intuitive subsections of the website). Con-
sequently, the website searches relied heavily on hand
search, which might be less reproducible than a search in a
literature database. Medical societies currently submit only
a fraction of their guidelines uploaded on their websites to
the FMH platform (fig. 2). The reason for the low submis-
sion rate might be the novelty of the platform and the effort
required to prepare and send a CPG to the platform. Fur-
thermore, medical societies’ websites did not contain 44
CPGs that were published in the literature only. According
to a survey at a Swiss university hospital, although physi-
cians thought guidelines are useful as a source of advice,
their use was limited by low awareness of existing guide-
lines, among other factors [15]. Making guidelines easier
to find and more accessible might improve their uptake in
Switzerland.
A range of terms are used to title CPGs in Switzerland.
Whereas more than half of the identified guidelines used
one of the predefined terms in their title (see fig. 3), only
a relatively small number were called a “guideline”. Even
though (only) the term “guideline” has an official defin-
ition in the Swiss CPG context [2], CPGs titled “guide-
line” were based on a systematic review of evidence no
more often than CPGs with other or no keywords in the ti-
tle (fig. 3). In contrast, the German translation of the term,
“Leitlinie”, was associated with a systematic review more
frequently. Some of the CPGs identified in this study were
documents with recommendations that potentially do not
intend to be a CPG, even if they could be interpreted and
used as such. This might point to a need for finer categori-
sation of recommendations for clinical practice, defining
some of these documents not as a guideline, but rather as a
less formal tool of communicating recommendations. Ad-
ditionally, a more rigid definition of “guidelines” could be
developed in consensus among Swiss developers and other
stakeholders. For example, in the German AWMF frame-
work the term “Leitlinie” is used in the context of CPG de-
velopment uniformly [16].
The development and endorsement process of CPGs seems
generally quite heterogeneous. In the health areas “cardio-
vascular disease” and “pregnancy and childbirth”, many
CPGs were either endorsed international guidelines or de-
veloped in cooperation with German or Austrian societies
(see table 1). In other health areas, no such pattern was
recognisable. CPGs produced in cooperation with other
countries were more frequently based on a systematic re-
view of evidence. Although our study cannot provide a de-
finitive conclusion on the quality of these CPGs, a system-
atic review is internationally considered an essential and
resource-intensive criterion for a high-quality CPG. Only
10% of CPGs were based on a systematic review of ev-
idence in our study. Systematic review was similarly un-
common in a study of Croatian CPGs (11.5%) and the
corresponding European CPGs (12.5%) [17]. Thus, inter-
national cooperation could be a possible strategy for pro-
viding CPGs in accordance with the international standard.
As a guideline’s development can cost up to USD 200,000
[18], it seems reasonable to look for synergies among de-
velopers.
Reporting quality of some aspects of the analysed Swiss
CPGs seemed rather low. Some of the shortcomings might
be related to the diverse reporting formats of some CPGs,
especially those published on the societies’ websites. For
example, the dissemination format of a leaflet or other type
of short guideline might omit references, even though they
have been used in the document’s development. If there
were no financial support for a guideline’s development,
the authors might not feel a need to report the fact and
might omit the information instead. However, the omission
of such information precludes evaluation of a guideline’s
quality by its users. Universal use of some reporting stan-
dard such as the RIGHT statement [19] would greatly help
to assess the trustworthiness of CPGs. Currently, only sin-
gle elements of CPG’s reporting quality can be compared
internationally; for example, conflict of interest was de-
clared in 44% of CPGs in our study, in 8% of Croatian and
92% of corresponding European CPGs [17], and 21% of
Australian CPGs [8].
Our study is currently the most comprehensive review of
CPGs in Switzerland. In comparison with the other men-
tioned national studies, we included a much broader range
of guidelines and sources in an effort to capture the real-
life situation. We employed a predefined systematic search
and data-extraction strategy, aiming for reproducible
methodology. The variables extracted were based on the
essential criteria for trustworthy CPGs, listed by GIN [13].
Our broad definition of CPGs meant that the majority of
CPGs did not contain information required for evaluation
with the AGREE-II [20] or RIGHT tools, commonly used
for guideline reporting assessment. Still, many correspond-
ing elements of these tools were represented in our extract-
ed variables.
Our study is also subject to some limitations. First, a few
CPGs might have been missed in the search, such as CPGs
published in other non-indexed Swiss speciality journals.
Second, we only extracted the absolute number of CGPs
per health area, which might not represent the extent of
guideline development activity in the respective area as
well as, for example, the total number of individual rec-
ommendations. Some CPGs also cover overlapping health
areas, which was not reflected well in our categorisation.
Third, we only analysed the quality of reporting, not the
comprehensive quality of the guideline itself. For example,
mentioning having used a systematic review might not
equal a high-quality systematic review being conducted
and interpreted appropriately. No formal conclusion re-
garding the overall quality of CPGs can be made as we did
not use validated tools, such as AGREE-II or the RIGHT-
checklist. Further, some imprecision could have happened
as both original and modified versions of the same guide-
line might have been included owing to the long timespan
(10 years) of publication dates included. Similarly, we did
not discriminate between the different dissemination for-
mats of the same guideline, such as long and short versions
as in the German AWMF framework. Additional docu-
ments describing the methodology of a CPG might not al-
ways have been found if they were provided in the soci-
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ety’s website but not mentioned within the guideline itself.
In those cases, we could underestimate the reporting qual-
ity. We also noticed that it is difficult to differentiate be-
tween guideline modification (adaptation) and de novo de-
velopment with another guideline used only as a source of
information. Therefore, any modification was categorised
as development of a (new) guideline. Finally, 136 CPGs
did not have one of the predefined keywords in the title
(fig. 3). Because of the heterogeneous formatting of the in-
cluded CPGs, we decided to extract keywords only from
the title, as it is identifiable in almost any kind of doc-
ument. However, the keyword in some cases might have
been present elsewhere – in the section heading in a jour-
nal, in the subtitle or abstract. This may have caused some
misclassification within this variable.
In conclusion, there is relevant CPG activity in Switzer-
land: the number of guidelines present is substantial, but
the quality of their development, transparency and meth-
ods reporting is widely varying. CPGs could potentially
be improved by using common definitions and standards
on development and reporting. In order to be able to com-
pare the quality of Swiss CPGs with that of other countries,
standard tools should be used for CPG reporting. We hope
that this study will facilitate discussions on the need of a
guideline framework in Switzerland by providing a first
general overview on Swiss CPGs developed by medical
societies.
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Appendix 1
Search protocol
Search strategy for clinical practice guidelines in PubMed,
OVID, non-indexed Swiss medical journals and Swiss
medical societies’ websites.
Appendix 2
List of the included Swiss clinical practice
guidelines
The appendices are available in a separate file for down-
loading at https://smw.ch/en/article/doi/smw.2019.20134/
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